Sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to Her2 status, as primary chemotherapy for localized invasive breast cancer patients: results of the planned interim analysis and analysis of predictive parameters. Supported by Phrc Aom/2002/02117, Pfizer inc., Roche, sanofi-aventis